|
Post by zuolun on Jul 12, 2014 19:28:41 GMT 7
Cordlife — Symmetrical Triangle Formation, crucial support @ S$1.13
|
|
|
Post by zuolun on Nov 8, 2014 11:57:56 GMT 7
Based on the Elliott Wave chart pattern dated 4 Sep 2013, Cordlife is riding on the corrective 3 waves down after it had completed the impulsive 5 waves up on 3 Sep 2013 (approx 5 qtrs). The share price collapsed to low of S$0.87 on 5 Nov 2014 indicated that the gap between S$1.08 to S$1.125 created on 26 Aug 2013 forming an island top was successfully covered. Cordlife — A "Waterfall Decline" chart pattern with 5 waves down, Interim TP S$0.82Cordlife closed with a bullish harami @ S$0.95 (+0.02, +2.2%) with thin volume done at 588 lots on 7 Nov 2014. Immediate support @ S$0.925, immediate resistance @ S$0.975. Cordlife (weekly) — Bearish Descending Triangle Breakout, TP S$0.74 Cordlife — The Elliott Wave Pattern as at 4 Sep 2013
|
|
|
Post by zuolun on Nov 12, 2014 16:55:37 GMT 7
Cordlife — A "Waterfall Decline" chart pattern with 5 waves down, Interim TP S$0.82Cordlife closed with a long black marubozu @ S$0.93 (-0.03, -3.1%) with thin volume done at 356 lots on 12 Nov 2014. Immediate support @ S$0.915, immediate resistance @ S$0.95.
|
|
|
Post by zuolun on Nov 13, 2014 15:22:40 GMT 7
Cordlife — A "Waterfall Decline" chart pattern with 5 waves down, Interim TP S$0.82Cordlife had a gravestone doji unchanged @ S$0.93 with thin volume done at 284 lots on 13 Nov 2014 at 4.10pm. Immediate support @ S$0.915, immediate resistance @ S$0.95. Cordlife (weekly) — Bearish Descending Triangle Breakout, TP S$0.74 There's a Chinese saying: 见好就收 = "Quit while you're ahead.".Blumont Vs CordlifeBlumont which collapsed suddenly 2 weeks after the strong sell signal had appeared on 19 Sep 2013 Vs Cordlife which actually had the strong sell signal appeared much earlier at record high @ S$1.46 on 4 Sep 2013 (island top reversal), prior to its share price collapsed to low of S$0.87 on 5 Nov 2014.
|
|
|
Post by zuolun on Nov 15, 2014 18:07:45 GMT 7
Cordlife in the red in Q1 due to fair value loss on investmentBy Lee Meixian 14 Nov 2014 CORDLIFE Group on Friday posted a S$3.6 million loss for its first quarter ended Sept 30, 2014, compared to a net profit of S$8.7 million a year ago. This was mainly due to a S$4.9 million fair value loss on its investment in China Cord Blood Corporation (CCBC). This fair value loss was computed based on the changes in CCBC's last traded price on June 30, 2014 of US$5.52, and Sept 30, 2014 of US$4.89. This contrasted against a year ago, when it enjoyed a fair value gain on CCBC of S$3.1 million. Revenue rose 17 per cent to S$13.3 million. This was due to an increase in the number of client deliveries, thanks to better awareness of the brand as a result of more marketing and client acquisition efforts. "In particular, there was an increase in marketing spend in the group's Indian subsidiary to increase brand awareness amongst its prospective clients and establish its presence in more cities," it said. The consumer healthcare company reported losses per share of 1.36 Singapore cents, versus earnings per share of 3.73 Singapore cents a year ago. It ended trading at S$0.91, down two Singapore cents.
|
|
|
Post by zuolun on Nov 17, 2014 7:02:58 GMT 7
|
|
|
Post by odie on Sept 13, 2015 16:00:21 GMT 7
Thursday, September 10, 2015 Cordlife Cordlife: (S$1.385) Jayhawk Capital urges CCBC's shareholders to reject offers Yesterday, the second largest shareholder of 13.4%-owned China Cord Blood Corp (CCBC), Jayhawk Capital, sent its second open letter to CCBC urging shareholders to reject all three privatisation offers. In the letter, the US-based private equity firm pointed to the "extremely low" privatisation offer of US$6.40/share by Golden Meditech (GM), and flagged that GM may raise its offer price to US$9-US$10/share, in response to the significantly higher offers by two other bidders. Jayhawk reiterated its view that CCBC is worth US$20-US$25, if the company heeds its call to: 1) Pay a special dividend of US$125m 2) Implement a US$125m share repurchase programme 3) Pay out regular dividends Further, the shareholder believes that CCBC may trade up to US$75-US$100 over the next 4-5 years, if it manages to achieve subscriber growth of 10-15%. The "fair value" prices dwarf CCBC's last traded share price of US$6.40. Nonetheless, Cordlife is sitting comfortably as the third largest shareholder in CCBC amid the ongoing bidding war. Maybank-KE's SOTP-derived TP of $1.53/share comprises $0.38/share worth of cash, derived from Cordlife realizing its 13.4% stake in CCBC via the offer from GM. Any other formal counter-offer would be a bonus. Posted by Alan Luo at 2:14 PM alanu6.blogspot.sg/2015/09/cordlife_10.html
|
|
|
Post by hope on Sept 14, 2015 10:23:24 GMT 7
Hi Odie
Wow, this stock is such a gem.
Is it too late to buy in now?
|
|
|
Post by odie on Sept 14, 2015 22:16:42 GMT 7
Hi Odie Wow, this stock is such a gem. Is it too late to buy in now? it is near the top of the top bollinger band buy when pull back at 1.23 the 20dma but you also need to monitor the China Cord Blood Corp NYSE: CO too for news
|
|
|
Post by odie on Sept 14, 2015 22:19:43 GMT 7
|
|
|
Post by odie on Sept 14, 2015 22:30:21 GMT 7
Hope,
do note that cordlife may never reach Maybank's target price of $1.53 as it is 1.42 now take analyst target prices with a pinch of salt
if i have to guess, i guess cordlife will hit 1.46 all punters in casino now LOL
Not vested
|
|
|
Post by odie on Nov 15, 2015 13:09:23 GMT 7
|
|